Compare EVGO & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGO | IMRX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | 331 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | 340.7M |
| IPO Year | N/A | 2021 |
| Metric | EVGO | IMRX |
|---|---|---|
| Price | $2.12 | $5.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $5.23 | ★ $17.20 |
| AVG Volume (30 Days) | ★ 4.6M | 708.8K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.45 | N/A |
| Revenue Next Year | $29.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.64 | $1.10 |
| 52 Week High | $5.18 | $10.08 |
| Indicator | EVGO | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 54.39 |
| Support Level | $1.64 | $5.34 |
| Resistance Level | $3.27 | $5.80 |
| Average True Range (ATR) | 0.11 | 0.31 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 97.06 | 70.00 |
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.